{"entity":{"id":"nct07336823","kind":"trial","name":"JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1 trial of JY232 run by Shenzhen Genocury Biotech Co., Ltd., now recruiting.","summary":"JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07336823 by Shenzhen Genocury Biotech Co., Ltd., with 9 participants planned, started 2026-01-20, primary completion expected 2028-12-31. Conditions recorded: Multiple Myeloma. Interventions recorded: JY232 Injection.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07336823","url":"https://clinicaltrials.gov/study/NCT07336823"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["jy232"],"companies":["genocury-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07336823","phase":"1","setting":"A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of JY232 Injection in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"Shenzhen Genocury Biotech Co., Ltd.","enrolled":9,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07336823/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"jy232","kind":"drug","name":"JY232","route":"/drugs/jy232/"}],"company":[{"id":"genocury-biotech","kind":"company","name":"Genocury Biotech","route":"/companies/genocury-biotech/"}]}}